Yahoo Finance

Amarantus BioScience President and CEO Publishes New Blog Entitled “#C4CT Concussion Awareness Summit – The Emergence of mTBI in the Concussion Debate”

Amarantus BioScience, Inc. (AMBS) today published a new blog post on The Chairman’s Blog, written by the company’s President and CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online ...
Yahoo Finance

Amarantus BioScience CEO Publishes New Blog Entitled “Unlocking Shareholder Value as Milestones Approach: Uplisting in 2014"

Amarantus BioScience, Inc. (OTCQB:AMBS) published a new blog post on The Chairman’s Blog, written by the company’s CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media ...
CNBC

Amarantus BioSciences Announces Landmark MANF Genomics Publication

SUNNYVALE, Calif., Oct. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including Parkinson's disease ...
CNBC

Amarantus BioSciences Provides Update to Shareholders

SUNNYVALE, Calif., Oct. 10, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic ...
FierceBiotech

Amarantus scores a small victory in the advance of its Alzheimer's Dx test

Alzheimer's watchers are left for the moment focusing on small victories. Amarantus Bioscience Holdings recently accomplished one, completing enrollment in a planned study of 72 patients to assess the ...
Nasdaq

Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics

Patent covers use of MANF in Glaucoma, Wolfram Syndrome and Retinitis Pigmentosa Amarantus has entered into a binding term sheet to license MANF to Emerald Organic Products. The transaction is ...
GEN

Amarantus Pays Power3 $0.5M for Biomarker IP to Diagnose Parkinson Disease

Amarantus will develop serum test to diagnose and monitor PD alongside its therapeutic candidate, MANF. Amarantus BioSciences is paying Power3 Medical Products $500,000 in cash and stock to license ...
FierceBiotech

Amarantus BioSciences Expands Corporate Strategy

SUNNYVALE, Calif.--(BUSINESS WIRE)-- Amarantus BioSciences, Inc. (OTCBB:AMBS), a biotechnology company developing MANF, a first-in-class disease–modifying therapeutic protein, today provided ...
Nasdaq

Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus ...
PR Newswire

Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries

Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the "Company," or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine ...
Business Insider

Amarantus Provides Recapitalization Update to Shareholders

Pending license with Emerald provides opportunity to realize therapeutic portfolio value JV w/Todos announces full enrollment for LymPro Alzheimer’s blood test clinical trial Amarantus management ...